Hopes Raised for More Sustainable Oligonucleotide Manufacturing

Why It Matters

A shift to enzymatic manufacturing could cut environmental impact and operating costs for the rapidly growing oligonucleotide therapeutics market, reshaping supply‑chain economics.

Key Takeaways

• Enzymatic synthesis cuts solvent consumption versus solid‑phase methods
• Current enzyme repertoire restricts range of producible oligos
• Scaling enzymatic processes above 100 g remains challenging
• Reaction speed of enzymes lags behind chemical synthesis
• Commercial players likely to adopt post‑market as technology matures

Pulse Analysis

The oligonucleotide sector, driven by RNA‑based vaccines and gene‑editing therapies, now accounts for billions in annual sales. Traditional solid‑phase synthesis, while reliable, demands large volumes of organic solvents, inflating the process mass intensity (PMI) metric and raising sustainability concerns. Industry analysts estimate that solvent waste accounts for a significant portion of manufacturing costs, prompting firms to explore greener alternatives that align with ESG goals and regulatory pressure.

Enzymatic synthesis mimics nature’s aqueous pathways, using polymerases and ligases to stitch nucleotides together. This approach dramatically reduces solvent use and can lower PMI, but it hinges on a robust catalog of engineered enzymes capable of handling diverse sequences. Presently, the limited enzyme toolbox restricts product variety, and scaling reactions beyond the 100‑gram benchmark proves difficult. Moreover, enzymatic steps often require longer incubation times, making them slower than the rapid, automated cycles of solid‑phase chemistry.

Despite technical obstacles, capital inflows into nucleic‑acid therapeutics have surged, providing the financial runway to refine enzymatic platforms. Companies like QurAlis argue that commercial‑scale manufacturers will transition to enzymatic methods once they achieve comparable throughput and cost parity. Such a shift could lower operational expenditures, reduce hazardous waste, and enhance the industry’s sustainability profile, ultimately benefiting investors, regulators, and patients alike.